Simcere-Tobishi merger lawsuit verdict sets precedent in China, SAMR says
In a landmark ruling, a Chinese court has upheld the antitrust regulator's conditional approval of the merger between Hong Kong-listed pharma company Simcere and rival Beijing Tobishi, dismissing the latter's challenge....To view the full article, register now.
Already a subscriber? Click here to view full article